| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/25/2001 | WO2000072833A3 Pharmaceutical preparations for inhibiting sphingomyelinase |
| 05/25/2001 | WO2000071114A8 Salts of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate] |
| 05/25/2001 | WO2000064426A3 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 05/25/2001 | WO2000061191A3 Heat stable coated colloidal iron oxides |
| 05/25/2001 | WO2000059489A3 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 05/25/2001 | WO2000051571B1 Capsule system |
| 05/25/2001 | WO2000042998A9 Multiparticulate bisoprolol formulation |
| 05/25/2001 | WO2000039081A3 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 05/25/2001 | WO2000032555A8 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 05/25/2001 | WO2000010588A3 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 05/25/2001 | WO2000010582A8 Probiotic, lactic acid-producing bacteria and uses thereof |
| 05/25/2001 | WO1999033841B1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 05/25/2001 | WO1998000091A3 Antifungal agents |
| 05/25/2001 | CA2720361A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2402811A1 Pharmaceutical composition for treatment of diarrhea |
| 05/25/2001 | CA2392093A1 Use of nsaids for the treatment of pancreatic cancer |
| 05/25/2001 | CA2392085A1 Carvedilol methanesulfonate |
| 05/25/2001 | CA2392059A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 05/25/2001 | CA2391968A1 An improved pharmaceutical composition for treating male erectile dysfunction |
| 05/25/2001 | CA2391913A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | CA2391654A1 Aryloxy propanolamines for improving livestock production |
| 05/25/2001 | CA2391622A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | CA2391603A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | CA2391598A1 Novel amidine derivatives, preparation and use thereof as medicines |
| 05/25/2001 | CA2391502A1 Aplidine treatment of cancers |
| 05/25/2001 | CA2391498A1 Substituted 1-benzazepines and derivatives thereof |
| 05/25/2001 | CA2391429A1 Solid state forms of 5-¬¬6-¬(2-fluorophenyl)methoxy|-2-naphthalenyl|methyl|-2,4-thiazolidinedione |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | CA2391396A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | CA2391382A1 Phorboxazole derivatives for treating cancer |
| 05/25/2001 | CA2391291A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | CA2391212A1 Methods and compositions for identifying disease markers |
| 05/25/2001 | CA2391100A1 .beta.-d-5-thioxylose derivatives, preparation method and therapeutic use |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2391084A1 High order nucleic acid based structures |
| 05/25/2001 | CA2390607A1 Materials and methods for detection and treatment of breast cancer |
| 05/25/2001 | CA2390548A1 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 05/25/2001 | CA2390431A1 Treatment of subnormal bone mineral density |
| 05/25/2001 | CA2390071A1 Aza compounds having neuronal activity |
| 05/25/2001 | CA2390051A1 Thymidylate synthase polymorphism for predicting chemotherapeutic response |
| 05/25/2001 | CA2389662A1 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/25/2001 | CA2389613A1 Continuous-flow method for preparing microparticles |
| 05/25/2001 | CA2389604A1 New use and novel n-azabicyclo-amide derivatives |
| 05/25/2001 | CA2389289A1 Mammalian toxicological response markers |
| 05/25/2001 | CA2388922A1 23 human secreted proteins |
| 05/25/2001 | CA2388846A1 Novel composition and use |
| 05/25/2001 | CA2388844A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | CA2388807A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2388777A1 18 human secreted proteins |
| 05/25/2001 | CA2388705A1 Treatment of sle with dehydroepiandrosterone |
| 05/25/2001 | CA2387809A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 05/25/2001 | CA2386579A1 Neurophilin ligands for treating ocular conditions |
| 05/25/2001 | CA2386318A1 Pesticidal aminoheterocyclamide compounds |
| 05/25/2001 | CA2380532A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 05/25/2001 | CA2360430A1 Cosmetic composition comprising at least a film-forming polymer and at least a regulating agent |
| 05/24/2001 | US20010001800 The xanthene compound reacts with nitric oxide to give a triazole fluorescent compound that emits strong fluorescence by irradiation with excitation light of long wavelength |
| 05/24/2001 | US20010001799 Anticoagulant |
| 05/24/2001 | US20010001791 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| 05/24/2001 | US20010001790 Topical formulations comprising skin penetration agents and the use thereof |
| 05/24/2001 | US20010001788 Applying an aqueous solution of squid chitosan which exhibits antihistamine activity to an affected portion of the subject suffering from allergic dermatitis |
| 05/24/2001 | US20010001783 Retinol stabilized cleansing compositions |
| 05/24/2001 | US20010001658 Granule modulating hydrogel system |
| 05/24/2001 | US20010001657 Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| 05/24/2001 | CA2326550A1 Method for treating migraine symptoms |
| 05/24/2001 | CA2326549A1 Method for treating migraine symptoms with ibuprofen and salts thereof |
| 05/24/2001 | CA2290316A1 Novel source of eleutherobin and related antimitotic diterpenes |
| 05/23/2001 | EP1101820A1 Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 05/23/2001 | EP1101770A1 Derivatives of 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazole and 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazole, their process of preparation and pharmaceutical compositions containing them |
| 05/23/2001 | EP1101769A2 Nitrogen Containing Erythromycin Derivatives |
| 05/23/2001 | EP1101765A2 Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them |
| 05/23/2001 | EP1101763A2 Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| 05/23/2001 | EP1101757A1 Heterocyclic compounds as tachykinin receptor antagonists |
| 05/23/2001 | EP1101756A1 Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| 05/23/2001 | EP1101497A1 STABILIZED PREPARATIONS OF $g(b)-LACTAM ANTIBIOTIC |
| 05/23/2001 | EP1101496A1 Therapeutic agents for allergic diseases |
| 05/23/2001 | EP1101493A2 New combination of formoterol and budesonide |
| 05/23/2001 | EP1101492A1 Novel remedies for allergic diseases |
| 05/23/2001 | EP1101112A2 Leptin-mediated gene-induction |
| 05/23/2001 | EP1100958A2 Nucleic acid molecules with specific identification of native prp?sc , their production and the use thereof |
| 05/23/2001 | EP1100946A1 Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| 05/23/2001 | EP1100945A2 Latency-active regulatory sequences of herpesviruses and lantency-inactive herpesviruses for gene transfer |
| 05/23/2001 | EP1100920A2 Nucleic acids and proteins from group b streptococcus |
| 05/23/2001 | EP1100916A2 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100910A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 05/23/2001 | EP1100896A1 Dna encoding snorf33 receptor |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100892A1 Use of prohibitin rna in treatment of cancer |
| 05/23/2001 | EP1100887A1 Growth differentiation factor-11 |
| 05/23/2001 | EP1100886A1 Tumor necrosis factor-gamma |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100879A1 Pneumococcal nrdg protein |
| 05/23/2001 | EP1100878A2 Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy |
| 05/23/2001 | EP1100870A1 Improvement of cardiac function by mesenchymal stem cell transplantation |
| 05/23/2001 | EP1100869A1 98 human secreted proteins |
| 05/23/2001 | EP1100830A2 Heterominibodies |
| 05/23/2001 | EP1100826A1 Isoforms of human calcium sensing receptor |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100817A1 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |